site banner

Eli Lilly releases data for a new weight-loss drug to tackle obesity : Shots - Health News : NPR

npr.org

This drug is a true gamechanger

In the SURMOUNT-1 study, people who took the highest dose of tirzepatide, most of whom had a BMI of about 30 or higher but did not have diabetes, lost about 21% of their body weight during the 72 week study. As researchers point out, for people who have bariatric surgery, typical weight loss is about 25% to 30% of their weight, one or two years after the surgery. In the tirzepatide study, 36% of people taking the highest dose lost 25% or more of their body weight.

this is comparable to bariatric surgery

11
Jump in the discussion.

No email address required.

It'll be absolutely fascinating to see the social changes that accompany a family of drugs that make obesity, if not optional, then at least curable. Particularly if national health services subsidize these drugs to make them affordable.

I'm envisioning a situation where a GLP-1 agonist prescription is as normal as eyeglasses for the middle aged. Obese people could become as unusual a sight as they were a century ago.